Literature DB >> 28432939

The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample.

Noa Krawczyk1, Kenneth A Feder2, Brendan Saloner2, Rosa M Crum3, Marc Kealhofer4, Ramin Mojtabai5.   

Abstract

BACKGROUND: Psychiatric disorders are highly comorbid with substance use disorders and play an important role in their course and recovery. However, the impact of comorbidity on treatment outcomes has not been examined in a U.S. national sample. This study explores the impact of psychiatric comorbidity on treatment completion among individuals admitted to publicly funded substance use treatment facilities across the United States.
METHODS: Using data on first-time treatment episodes in the U.S. from the Treatment Episode Dataset-Discharges (TEDS-D) for the years 2009-2011, logistic regression was used to assess the association between psychiatric comorbidity and treatment non-completion, and Cox proportional hazards regression was used to assess the association between comorbidity and rate of attrition. Analyses were performed for all substances together and then stratified by primary substance of abuse (alcohol, cannabis, stimulants, or opioids).
RESULTS: Of 856,385 client treatment episodes included in our analysis, 28% had a psychiatric comorbidity and 38% did not complete treatment. After adjusting for socio-demographic and treatment characteristics, clients with psychiatric comorbidity had higher odds of not completing treatment relative to those without comorbidity [OR=1.28 (1.27-1.29)], and had an earlier time to attrition [HR=1.14 (1.13-1.15)]. Psychiatric comorbidity was most strongly associated with treatment non-completion and rate of attrition in those admitted primarily for alcohol [OR=1.37 (1.34-1.39); HR=1.19 (1.17-1.21), respectively].
CONCLUSIONS: Individuals with psychiatric comorbidities receiving treatment for substance use disorders face unique challenges that impact their ability to complete treatment. The findings call for further efforts to integrate treatment for psychiatric comorbidities in substance use treatment settings.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol treatment; Comorbidity; Drug treatment; Mental health integration; Substance use treatment; Treatment retention

Mesh:

Year:  2017        PMID: 28432939      PMCID: PMC5490486          DOI: 10.1016/j.drugalcdep.2017.02.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  51 in total

1.  Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment.

Authors:  Ya-Fen Chan; Michael L Dennis; Rodney R Funk
Journal:  J Subst Abuse Treat       Date:  2007-06-15

2.  Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach.

Authors:  Pia M Mauro; C Debra Furr-Holden; Eric C Strain; Rosa M Crum; Ramin Mojtabai
Journal:  Drug Alcohol Depend       Date:  2016-04-07       Impact factor: 4.492

3.  Barriers to optimal care for patients with coexisting substance use and mental health disorders.

Authors:  Fraser C Todd; J Douglas Sellman; Paul J Robertson
Journal:  Aust N Z J Psychiatry       Date:  2002-12       Impact factor: 5.744

4.  The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders.

Authors:  M Driessen; S Meier; A Hill; T Wetterling; W Lange; K Junghanns
Journal:  Alcohol Alcohol       Date:  2001 May-Jun       Impact factor: 2.826

5.  A comparative evaluation of substance abuse treatment IV. The effect of comorbid psychiatric diagnoses on amount of treatment, continuing care, and 1-year outcomes.

Authors:  P C Ouimette; K Gima; R H Moos; J W Finney
Journal:  Alcohol Clin Exp Res       Date:  1999-03       Impact factor: 3.455

6.  Interaction of motivation and psychiatric symptoms on substance abuse outcomes in sober living houses.

Authors:  Douglas L Polcin; Rachael A Korcha; Jason C Bond
Journal:  Subst Use Misuse       Date:  2014-10-07       Impact factor: 2.164

7.  The role of psychiatric disorders in predicting drug dependence treatment outcomes.

Authors:  Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

8.  DSM-III-R alcohol abuse and dependence and psychiatric comorbidity in Ontario: results from the Mental Health Supplement to the Ontario Health Survey.

Authors:  H E Ross
Journal:  Drug Alcohol Depend       Date:  1995-08       Impact factor: 4.492

9.  Gender differences in the comorbidity of smoking behavior and major depression.

Authors:  Mathilde M Husky; Carolyn M Mazure; Prashni Paliwal; Sherry A McKee
Journal:  Drug Alcohol Depend       Date:  2007-09-11       Impact factor: 4.492

Review 10.  Psychiatric Comorbidity and Complications.

Authors:  Michael J Mason; Alexis Aplasca; Rosa Morales-Theodore; Nikola Zaharakis; Julie Linker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2016-04-16
View more
  15 in total

1.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

2.  Randomized clinical trial evaluating the preliminary effectiveness of an integrated anxiety disorder treatment in substance use disorder specialty clinics.

Authors:  Kate Wolitzky-Taylor; Jennifer Krull; Richard Rawson; Peter Roy-Byrne; Richard Ries; Michelle G Craske
Journal:  J Consult Clin Psychol       Date:  2018-01

3.  Substance use consequences, mental health problems, and readiness to change among Veterans seeking substance use treatment.

Authors:  David H Morris; Alan K Davis; Kirstin J Lauritsen; C Martin Rieth; Mark M Silvestri; Jamie J Winters; Stephen T Chermack
Journal:  J Subst Abuse Treat       Date:  2018-08-19

4.  Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.

Authors:  Phillip L Marotta; Kristi L Stringer; Amar D Mandavia; Alissa Davis; Leo Beletsky; Tim Hunt; Dawn Goddard-Eckrich; Elwin Wu; Louisa Gilbert; Nabila El-Bassel
Journal:  J Addict Dis       Date:  2019-12-10

Review 5.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

6.  Validation of brief screening measures for depression and anxiety in young people with substance use disorders.

Authors:  Kate H Bentley; Hitoshi Sakurai; Kelsey L Lowman; Lisa Rines-Toth; James McKowen; Paola Pedrelli; A Eden Evins; Amy M Yule
Journal:  J Affect Disord       Date:  2021-01-07       Impact factor: 4.839

7.  Staff experiences of encountering and treating outpatients with substance use disorder in the psychiatric context: a qualitative study.

Authors:  Elisabeth Petersén; Anna Thurang; Anne H Berman
Journal:  Addict Sci Clin Pract       Date:  2021-05-10

8.  National trends and characteristics of inpatient detoxification for drug use disorders in the United States.

Authors:  He Zhu; Li-Tzy Wu
Journal:  BMC Public Health       Date:  2018-08-29       Impact factor: 3.295

9.  Levels and predictors of participation in integrated treatment programs for pregnant and parenting women with problematic substance use.

Authors:  Thao Lan Le; Chris Kenaszchuk; Karen Milligan; Karen Urbanoski
Journal:  BMC Public Health       Date:  2019-02-06       Impact factor: 3.295

10.  Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

Authors:  Noa Krawczyk; Arthur Robin Williams; Brendan Saloner; Magdalena Cerdá
Journal:  J Subst Abuse Treat       Date:  2021-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.